Effect of Rosuvastatin in contrast induced nephropathy

The effect of Rosuvastatin on the incidence of contrast nephropathy in patients with chronic renal failure receiving contrast

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090905002417N21

Enrollment

350

Registered

2019-07-07

Start date

2018-01-21

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of Rosuvostatin in contrast induced nephropathy in chronic kidney disease. chronic kidney disease

Interventions

Intervention 1: Intervention group: 175 patients is entered in study that they have chronic kidney disease and their eGFR are 30-60mg/dL. one day before contrast administration, they eat 2 tablet Ros

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: absence of Statin use during past 3 months eGFR between 30 - 60 cc/min/1.73m2 not pregnant absence use of contrast during past 10 days absence use of Metformin

Exclusion criteria

Exclusion criteria: Acute coronary syndrome history of allergy to contrast media death during 72 hours after receiving contrast media end stage renal disease

Design outcomes

Primary

Measure	Time frame
Serum creatinin level. Timepoint: 48 hours after contrast media use. Method of measurement: autoanalyser.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact??Firouzeh Moeinzadeh

Esfahan University of Medical Sciences

fimoinzad@yahoo.com+98 31 3822 2267

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026